The global blockbuster oncology brands market size was valued at USD 28.75 billion in 2017. Heightened adoption of cancer immunotherapies in developed regions along with continual expansion of indications with accelerated approvals granting these therapies first-line treatment status is poised to drive the market during the forecast period.
Complexity in cancer treatment has risen for doctors with biomarker-based treatment options for patient subsets. These therapies are leading to the segmentation of patients within cancer types. However, the majority of recently launched therapies in the market for blockbuster oncology brands are increasingly serving the broader patient population, going beyond existing biomarker niches, and targeting approvals in the frontline settings.
Zejula, a fourth line treatment for recurrent ovarian cancer, recently gained U.S. FDA approval for its use, irrespective of BRCA mutation status, which sets it apart among other approved PARP inhibitors. Majority of the therapies have either obtained front line treatment approval or are in the process of collecting clinical trial evidence for approval. Higher efficacy and safety of these branded therapies, supported by long term overall survival and progression-free risk evidence, is likely to provide a significant boost to the market during the forecast period.
This market is highly competitive in nature and brand leadership is mainly based on manufacturer dominance in respective disease segments. For instance, Bristol-Myers-Squibb (BMS), Merck & Co. (Merck), and Roche are intensely competing in the NSCLC patient subset. Even though it has blockbuster therapies in its portfolio, Roche commands a low share, less than 10.0%, in the lung cancer segment; it is a prominent player in the breast cancer segment with more than 40.0% share.
In the race to gain a competitive advantage over competitors and widen their presence among other blockbuster oncology therapies, companies are primarily expanding indications and carrying out combination regimen clinical trials.
High annual treatment costs associated with immunotherapies can slow down penetration. In order to curtail the impact, companies have to succumb to pricing negotiations with regulatory agencies or forego immunotherapy availability in certain countries. Market players are, therefore, offering deals such as patient access programs and tiered pricing to ensure market access, especially in developing countries.
On the basis of brands, the market has been segmented into Opdivo, Keytruda, Ibrance, Perjeta, Tecentriq, Tagrisso, Darzalex, Revlimid, Imbruvica, Gazyva, and Zejula.
Opdivo, Revlimid, and Keytruda together accounted for the leading share in the market in 2017. Opdivo held the second-largest share in 2017 and was closely followed by Keytruda. Prominence of Opdivo and Keytruda is attributable to their high adoption in lung cancer treatment and wide availability worldwide. BMS is undertaking several clinical trials for expansion of its use in varied indications including solid tumors, prostate cancer, and glioblastoma.
On the basis of indication, the blockbuster oncology brands market has been divided into lymphoma, breast cancer, lung cancer, multiple myeloma, and others. Multiple myeloma was the dominant segment in the market in 2017 and was followed by lung cancer.
Lung cancer has one of the lowest survival rates and is one of the major causes of cancer mortality burden every year. In majority of cases, lung cancer is diagnosed at an advanced stage. Currently, Opdivo, Keytruda, Tecentriq, and Tagrisso serve as treatment options for either first or second line treatment of lung cancer. With recent FDA approvals, Keytruda and Opdivo are growing in prominence as blockbuster brands in use for frontline therapy. Other therapies are undergoing trials for expansion to include a wider target population. This trend is estimated to contribute to the growth of the lung cancer segment.
Breast cancer is associated with high mortality and prevalence among women. Perjeta and Ibrance are the FDA-approved immunotherapies used to treat breast cancer. Ibrance is approved for the treatment of HR+/HER2-, whereas Perjeta is approved for HER2+ breast cancer patient subsets. Patients falling under the HR+/HER2- type accounts for nearly 70.0% of the breast cancer burden, which reflected Ibrance’s larger share than Perjeta in the market in 2017.
Geographically, North America was the leading revenue contributor in the global market in 2018, with a share of more than 60.0%. The region is also anticipated to register noteworthy growth during the forecast period, thanks to the high availability of approved blockbuster oncology brands and favorable regulatory scenarios, which shortens time-to-market. In addition, with a higher average spending capacity, the response to hike in treatment costs is projected to be less adverse as compared to other regions.
Moreover, the U.S. FDA does not conduct cost-effectiveness appraisals of oncology brands for reimbursement approval, thereby facilitating faster market access for immunotherapies.
The market is characterized by the presence of a number of multinational companies, which are actively involved in collaborative indication expansion and combination-therapy development strategies for existing products. For instance, BMS collaborated with AbbVie to work on potential combination regimens with Opdivo in the treatment of solid tumors. Some of the key companies present in the market are Bristol Myers Squibb.; Merck& Co.; Pfizer, Inc.; Roche, Ltd; AstraZeneca Plc; and Tesaro, Inc.
Base year for estimation
Actual estimates/Historical data
2015 - 2016
2018 - 2027
Revenue in USD Million & CAGR from 2018 to 2027
North America, Europe, Asia Pacific, Latin America, MEA
Revenue forecast, company share, competitive landscape, growth factors and trends
U.S., Canada, U.K., Germany, Italy, Switzerland, France, Spain, Poland, Denmark, Japan, China, India, Australia, New Zealand, Hong Kong, Singapore, Philippines, South Korea, Indonesia, Brazil, Mexico, Argentina, Israel, Turkey, and Saudi Arabia
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2015 to 2027. For the purpose of this study, Grand View Research has segmented the global blockbuster oncology brands market report on the basis of indication, brands, and region:
Brands Outlook (Revenue, USD Million, 2015 - 2027)
Indication Outlook (Revenue, USD Million, 2015 - 2027)
Regional Outlook (Revenue, USD Million, 2015 - 2027)
Middle East & Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.